F

Foghorn Therapeutics
D

FHTX

5.24400
USD
-0.13
(-2.35%)
مغلق
حجم التداول
1,682
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
291,630,581
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AAPL
    AAPL
    -0.310
    (-0.13%)
    245.560 USD
    A
    AMC
    -0.06100
    (-1.75%)
    3.43000 USD
    AMD
    AMD
    -3.370
    (-2.95%)
    110.790 USD
    B
    BB
    -0.34000
    (-6.09%)
    5.24500 USD
    G
    GME
    -0.600
    (-2.22%)
    26.430 USD
    MSFT
    MSFT
    -7.96
    (-1.91%)
    408.15 USD
    N
    NOK
    -0.04500
    (-0.90%)
    4.94000 USD
    NVDA
    NVDA
    -5.850
    (-4.18%)
    134.260 USD
    S
    SNDL
    0.00500
    (0.28%)
    1.77000 USD
    TSLA
    TSLA
    -16.87
    (-4.76%)
    337.50 USD
    المزيد
الأخبار
المقالات

العنوان: Foghorn Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.